News
05-04-2010, 05:10 AM
Celsion Corporation, a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
More... (http://www.news-medical.net/news/20100504/Celsion-reports-2446-million-net-loss-from-operations-for-first-quarter-2010.aspx)
More... (http://www.news-medical.net/news/20100504/Celsion-reports-2446-million-net-loss-from-operations-for-first-quarter-2010.aspx)